VTP-38543 / AbbVie - LARVOL DELTA

COMBINED TARGETING OF LXR AND NF-ΚB AS A TREATMENT OF ATOPIC DERMATITIS (ISAD 2022) - "A transcriptomic meta- and enrichment analysis was performed, revealing the gene expression alterations associated with LXR and NF-κB modulation in lesional AD compared with non-atopic skin. Histological analysis of AD skin treated with an LXR agonist (VTP38543) showed no differences in p-65 NF-κB activation, tight junction, or Langerhans cells after treatment. The combined treat- ment with an LXR agonist (T0901317) and an NF-κB antagonist (JSH-23) on in vitro 2D and full-thickness AD models reveals an increased antimicrobial effect against S. aureus."

Late-breaking abstract • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

An Ascending Multiple Dose Study of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P1/2; N=104; Completed; Sponsor: Vitae Pharmaceuticals, Inc.; Recruiting ➔ Completed

Trial completion • Biosimilar • Dermatitis • Eczema

An Ascending Multiple Dose Study of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P1/2; N=100; Recruiting; Sponsor: Vitae Pharmaceuticals, Inc.

New P1/2 trial • Biosimilar • Dermatitis • Eczema